p38 mitogen-activated protein kinase and hematologic malignancies

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 11, 2009, Pages 1850-1856

  Feng, Yongdong ^a,b   Wen, Jianguo ^a   Chang, Chung Che ^a,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38;

APOPTOSIS; BONE MARROW DEPRESSION; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMIA; LYMPHOMA; REVIEW;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; ISOENZYMES; MYELODYSPLASTIC SYNDROMES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 70449348490     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74(10):589-607.
2. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci. 1994;19(11):470-473.
3. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265(5173):808-811. (Pubitemid 24266145)
4. McLaughlin MM, Kumar S, McDonnell PC, et al. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem. 1996;271(14):8488-8492. (Pubitemid 26108688)
5. Huang CK, Zhan L, Ai Y, Jongstra J. LSP1 is the major substrate for mitogen-activated protein kinase-activated protein kinase 2 in human neutrophils. J Biol Chem. 1997;272(1):17-19. (Pubitemid 27021115)
6. Thomas G, Haavik J, Cohen P. Participation of a stress-activated protein kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells. Eur J Biochem. 1997;247(3):1180-1189. (Pubitemid 27337076)
7. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol. 2001;21(19):6461-6469. (Pubitemid 32927414)
8. Pierrat B, Correia JS, Mary JL, Tomas-Zuber M, Lesslauer W. RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38alpha mitogen-activated protein kinase (p38alphaMAPK). J Biol Chem. 1998;273(45):29661-29671. (Pubitemid 28509976)
9. Lewis JS, Vijayanathan V, Thomas TJ, et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res. 2005;15(3):113-128. (Pubitemid 40978709)
10. Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 2006;25(47):6277-6290. (Pubitemid 44564744)
11. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem. 2005;280(12):10964-10973. (Pubitemid 40418398)
12. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277(33):29792-29802.
13. Chen Y, Miao ZH, Zhao WM, Ding J. The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11′-dideoxyverticillin-induced G2/M arrest. FEBS Lett. 2005;579(17):3683-3690. (Pubitemid 40897709)
14. Pedraza-Alva G, Koulnis M, Charland C, et al. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J. 2006;25(4):763-773.
15. Yih LH, Hsueh SW, Luu WS, Chiu TH, Lee TC. Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells. Carcinogenesis. 2005;26(1):53-63.
16. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle. 2006;5(8):824-828. (Pubitemid 44145574)
17. Bulavin DV, Fornace AJ Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95-118.
18. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4(4):372-377. (Pubitemid 38987064)
19. Jiang Y, Gram H, Zhao M, et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem. 1997;272(48):30122-30128. (Pubitemid 27512210)
20. Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem. 1997;272(38):23668-23674. (Pubitemid 27410940)
21. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275(5296):90-94. (Pubitemid 27020316)
22. Enslen H, Brancho DM, Davis RJ. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J. 2000;19(6):1301-1311. (Pubitemid 30151026)
23. Schoorlemmer J, Goldfarb M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J Biol Chem. 2002;277(51):49111-49119. (Pubitemid 36014339)
24. Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science. 1998;280(5363):599-602. (Pubitemid 28227765)
25. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci U S A. 2004;101(1):147-152. (Pubitemid 38084218)
26. Ohta T, Eguchi R, Suzuki A, Miyakaze S, Ayuzawa R, Kaji K. Hypoxia-induced apoptosis and tube breakdown are regulated by p38 MAPK but not by caspase cascade in an in vitro capillary model composed of human endothelial cells. J Cell Physiol. 2007;211(3):673-681. (Pubitemid 46683035)
27. Verma A, Mohindru M, Deb DK, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002;277(47):44988-44995. (Pubitemid 36159097)
28. McDonnell PC, DiLella AG, Lee JC, Young PR. Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6q21.3/21.2. Genomics. 1995;29(1):301-302.
29. Goedert M, Hasegawa J, Craxton M, Leversha MA, Clegg S. Assignment of the human stress-activated protein kinase-3 gene (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization. Genomics. 1997;41(3):501-502. (Pubitemid 27194810)
30. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem. 1996;271(30):17920-17926. (Pubitemid 26250772)
31. Hanks SK, Hunter T. Protein kinases 6: the eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995;9(8):576-596.
32. Zhou L, Opalinska J, Verma A. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell Cycle. 2007;6(5):534-537. (Pubitemid 46440424)
33. Navas TA, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006;108(13):4170-4177. (Pubitemid 44913289)
34. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446-451.
35. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273(3):1741-1748. (Pubitemid 28133705)
36. Camps M, Nichols A, Gillieron C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science. 1998;280(5367):1262-1265. (Pubitemid 28269620)
37. Muda M, Theodosiou A, Rodrigues N, et al. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem. 1996;271(44):27205-27208. (Pubitemid 26367265)
38. Tanoue T, Yamamoto T, Maeda R, Nishida E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem. 2001;276(28):26629-26639. (Pubitemid 37412886)
39. Meskiene I, Baudouin E, Schweighofer A, et al. Stress-induced protein phosphatase 2C is a negative regulator of a mitogen-activated protein kinase. J Biol Chem. 2003;278(21):18945-18952. (Pubitemid 36799278)
40. Pramanik R, Qi X, Borowicz S, et al. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun: the determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem. 2003;278(7):4831-4839. (Pubitemid 36800988)
41. Nemoto S, Xiang J, Huang S, Lin A. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998;273(26):16415-16420. (Pubitemid 28311422)
42. Guo YL, Kang B, Han J, Williamson JR. p38beta MAP kinase protects rat mesangial cells from TNF-alpha-induced apoptosis. J Cell Biochem. 2001;82(4):556-565. (Pubitemid 32720671)
43. Behren A, Binder K, Vucelic G, et al. The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells. Exp Cell Res. 2005;303(2):321-330. (Pubitemid 40126266)
44. Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol. 2000;20(13):4543-4552. (Pubitemid 30396102)
45. Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D. Selective activation of p38alpha and p38gamma by hypoxia: role in regulation of cyclin D1 by hypoxia in PC12 cells. J Biol Chem. 1999;274(33):23570-23576. (Pubitemid 129529198)
46. Balasubramanian S, Efimova T, Eckert RL. Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J Biol Chem. 2002;277(3):1828-1836. (Pubitemid 34968756)
47. Molnar A, Theodoras AM, Zon LI, Kyriakis JM. Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J Biol Chem. 1997;272(20):13229-13235. (Pubitemid 27216750)
48. Bulavin DV, Amundson SA, Fornace AJ. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev. 2002;12(1):92-97.
49. Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein HS, Manthey CL. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res. 1999;48(10):533-538. (Pubitemid 29495635)
50. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003;27(11):999-1007. (Pubitemid 36809073)
51. Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411(6833):102-107. (Pubitemid 32428198)
52. Mikhailov A, Shinohara M, Rieder CL. The p38-mediated stress-activated checkpoint: a rapid response system for delaying progression through antephase and entry into mitosis. Cell Cycle. 2005;4(1):57-62. (Pubitemid 41038928)
53. Yee AS, Paulson EK, McDevitt MA, et al. The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. Gene. 2004;336(1):1-13.
54. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270(5240):1326-1331.
55. Pugazhenthi S, Miller E, Sable C, et al. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem. 1999;274(39):27529-27535. (Pubitemid 129527797)
56. Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273(4):2161-2168. (Pubitemid 28069266)
57. De Chiara G, Marcocci ME, Torcia M, et al. Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem. 2006;281(30):21353-21361. (Pubitemid 44115474)
58. Choi SY, Kim MJ, Kang CM, et al. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J Biol Chem. 2006;281(11):7049-7059.
59. Capano M, Crompton M. Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J. 2006;395(1):57-64.
60. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006;281(30):21256-21265.
61. Cuadrado A, Lafarga V, Cheung PC, et al. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J. 2007;26(8):2115-2126. (Pubitemid 46625792)
62. Furusu A, Nakayama K, Xu Q, Konta T, Kitamura M. MAP kinase-dependent, NF-kappaB-independent regulation of inhibitor of apoptosis protein genes by TNF-alpha. J Cell Physiol. 2007;210(3):703-710. (Pubitemid 46185040)
63. Sethi G, Ahn KS, Xia D, Kurie JM, Aggarwal BB. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products. J Immunol. 2007;179(3):1926-1933.
64. Seo SK, Lee HC, Woo SH, et al. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007;12(1):195-209.
65. Cheng Y, Chang LW, Tsou TC. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol. 2006;80(6):310-318. (Pubitemid 43725214)
66. Rudolf E, Rudolf K, Cervinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol. 2007. (Pubitemid 351311388)
67. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 2003;22(13):2034-2044. (Pubitemid 36523640)
68. Stoica BA, Movsesyan VA, Knoblach SM, Faden AI. Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol Cell Neurosci. 2005;29(3):355-371.
69. Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol. 2008;140(2):169-180. (Pubitemid 350265041)
70. Nagata Y, Moriguchi T, Nishida E, Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood. 1997;90(3):929-934. (Pubitemid 27314124)
71. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002;277(10):7726-7735. (Pubitemid 34968219)
72. Kim JM, White JM, Shaw AS, Sleckman BP. MAPK p38 alpha is dispensable for lymphocyte development and proliferation. J Immunol. 2005;174(3):1239-1244.
73. Katsoulidis E, Li Y, Mears H, Platanias LC. The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res. 2005;25(12):749-756. (Pubitemid 43068486)
74. Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood. 2000;96(3):933-940.
75. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 2000;102(2):221-231.
76. Katsoulidis E, Li Y, Yoon P, et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res. 2005;65(19):9029-9037. (Pubitemid 41377395)
77. Uddin S, Lekmine F, Sharma N, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000;275(36):27634-27640. (Pubitemid 30688871)
78. Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998;17(10):2817-2829. (Pubitemid 28227128)
79. Lee J, Shin JS, Park JY, et al. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis-inducing ligand induced by interferon-gamma in fetal brain astrocytes. J Neurosci Res. 2003;74(6):884-890. (Pubitemid 37490421)
80. Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci. 2007;81(19-20):1452-1460.
81. Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007;131(12):1789-1793. (Pubitemid 350294578)
82. Shahjahan M, Dunphy CH, Ewton A, et al. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Am J Clin Pathol. 2008;130(4):635-641.
83. Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem. 2001;276(6):4012-4019. (Pubitemid 37371483)
84. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002;16(4):683-692.
85. Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene. 2002;21(30):4601-4612. (Pubitemid 34833138)
86. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem. 2001;276(30):28570-28577. (Pubitemid 37391572)
87. Chen CH, Lin JY, Liu FH, Chang JL, Huang HM. Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells. Ann Hematol. 2008;87(3):175-182.
88. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 2002;99(4):1314-1319. (Pubitemid 34547086)
89. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999;1(2):94-97. (Pubitemid 129501950)
90. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667-4679. (Pubitemid 36857719)
91. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55-72.
92. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21(15):4104-4113. (Pubitemid 34857442)
93. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98(9):2784-2790. (Pubitemid 33789768)
94. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101(2):703-705. (Pubitemid 36077596)
95. Nguyen AN, Stebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res. 2006;312(10):1909-1923. (Pubitemid 43776012)